Tuesday, March 20, 2018

Antibe Therapeutics Inc. - ATE.v

Antibe Therapeutics Inc. - ATE.v develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation.
On March 20, 2018 the company released NEWS

Antibe Therapeutics Inc.'s lead drug, ATB-346, met its primary end point in the phase 2B gastrointestinal safety study. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of ATB-346 in GI safety compared with naproxen, the most prescribed nonsteroidal anti-inflammatory drug in the United States. Subjects on ATB-346 exhibited an ulceration rate of 2.5 per cent versus an ulceration rate of 42.1 per cent for subjects on naproxen at the end of the two-week treatment period, with a very high degree of statistical significance (p was less than 0.001). ATB-346 was also safe and well tolerated.
______________________________
On February 26, 2018 the company released NEWS

Antibe Therapeutics Inc. would like to confirm the previously announced timing for its Phase 2B double-blind clinical trial of ATB-346. The final subject has now completed treatment and the subsequent two-week monitoring period. The CRO conducting the study, Topstone Research Inc. , is currently performing data validation and analysis. Antibe remains on its previously announced schedule and anticipates being in a position to report top-line results during the week of March 19th, 2018.